- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab SAR440340, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Fresno, California • Palm Springs, California + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 3,292 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- LY3650150, Placebo, Standard therapy for INCS
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction
- Interventions
- LY3540378, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Covina, California • Northridge, California + 18 more
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- Remternetug (SC), Matching Placebo (Remternetug)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2034
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
- Conditions
- Hypertension
- Interventions
- Placebo, ISIS 757456
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tustin, California + 6 more
- Conditions
- Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
- Interventions
- Darbepoetin, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 1 Hour to 24 Hours
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
- Conditions
- Smoking Cessation, Weight Gain
- Interventions
- Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
- Interventions
- Volanesorsen
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 8
- States / cities
- Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 11
- States / cities
- Chula Vista, California • La Jolla, California • Rialto, California + 8 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 8
- States / cities
- North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
- Conditions
- Ankylosing Spondylitis
- Interventions
- Sarilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more
- Conditions
- Severe Asthma
- Interventions
- GB-0895, Placebo
- Drug
- Lead sponsor
- Generate Biomedicines
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 786 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Inglewood, California • Lancaster, California + 14 more
- Conditions
- Healthy Subjects
- Interventions
- AC-076 for s.c. administration, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab + TCS, Placebo + TCS
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Palo Alto, California + 11 more
- Conditions
- Obesity, Overweight
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
- Conditions
- Diabetes Type 2
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Canoga Park, California + 25 more
- Conditions
- Low Back Pain
- Interventions
- Fasinumab, placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 938 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- adalimumab, methotrexate, placebo
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
- Conditions
- Congestive Heart Failure
- Interventions
- Nesiritide, Tadalafil, Placebo, Saline load
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota